Last reviewed · How we verify

Cefadroxil tablets manufactured by GSK

GlaxoSmithKline · FDA-approved active Small molecule

Cefadroxil inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins and cross-linking peptidoglycan strands.

Cefadroxil inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins and cross-linking peptidoglycan strands. Used for Bacterial infections caused by susceptible organisms including skin and soft tissue infections, Urinary tract infections, Respiratory tract infections.

At a glance

Generic nameCefadroxil tablets manufactured by GSK
SponsorGlaxoSmithKline
Drug classFirst-generation cephalosporin
TargetPenicillin-binding proteins (PBPs)
ModalitySmall molecule
Therapeutic areaInfectious Disease
PhaseFDA-approved

Mechanism of action

Cefadroxil is a first-generation cephalosporin antibiotic that works by disrupting the formation of bacterial cell walls. It binds to penicillin-binding proteins and prevents cross-linking of peptidoglycan, leading to cell wall instability and bacterial cell lysis. This bactericidal mechanism is effective against a broad spectrum of gram-positive and some gram-negative bacteria.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: